Enanta Pharmaceuticals, Inc. (ENTA) News
Filter ENTA News Items
ENTA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ENTA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ENTA News From Around the Web
Below are the latest news stories about ENANTA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ENTA as an investment opportunity.
Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceWATERTOWN, Mass., January 08, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2024 at 8:15 a.m. PT in San Francisco, CA. |
Sector Update: Health Care Stocks Mixed Tuesday AfternoonHealth care stocks were mixed in Tuesday afternoon trading, with the NYSE Health Care Index easing 0 |
Top Midday DeclinersDiana Shipping (DSX) has extended the time charter contract for its m/v Amphitrite dry bulk vessel, |
Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement LawsuitWATERTOWN, Mass., December 24, 2024--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts ("the Court") has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta’s patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 ("the ’953 Patent") |
Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last?Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. |
Enanta’s zelicapavir shows promise in paediatric respiratory syncytial virus trialThe trial enrolled a total of 96 participants, with 70 receiving zelicapavir and 26 receiving placebo. |
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)WATERTOWN, Mass., December 09, 2024--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced positive topline results from the first-in-pediatrics Phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory syncytial virus (RSV). An antiviral effect was observed for the primary and secondary virology endpo |
Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)WATERTOWN, Mass., December 06, 2024--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the company will hold a conference call and webcast on Monday, December 9 at 8:30 a.m. ET to share topline results from RSVPEDs, a first-in-pediatrics Phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory syn |
Enanta Pharmaceuticals’ Reduced Reporting: Potential Impact on Investor Appeal and Stock VolatilityEnanta Pharmaceuticals (ENTA) has disclosed a new risk, in the Share Price & Shareholder Rights category. Enanta Pharmaceuticals, as a smaller reporting company under the Exchange Act, may opt to utilize reduced reporting and disclosure obligations, potentially impacting investor appeal and the market activity of its common stock. These exemptions include limited executive compensation disclosures and a requirement of only two years of audited financial statements, which may lead to heightened s |
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue EstimatesEnanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -17.24% and 20.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |